Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.48 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.48 |
| ▸ | PRKAB2 | O43741 | 6/20 | 0.41 |
| ▸ | PRKAG1 | P54619 | 6/20 | 0.41 |
| ▸ | PRKAA2 | P54646 | 6/20 | 0.41 |
| ▸ | PRKAA1 | Q13131 | 6/20 | 0.41 |
| ▸ | PRKAG3 | Q9UGI9 | 6/20 | 0.41 |
| ▸ | PRKAG2 | Q9UGJ0 | 6/20 | 0.41 |
| ▸ | PRKAB1 | Q9Y478 | 6/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 4/20 | 0.36 |
| ▸ | RAB9A | P51151 | 4/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1041484 | 0.71 | — | — | |
| SCHEMBL29953860 | 0.71 | TSHR (0.40) | HCAR2RAB9AMEN1KMT2ADAO | |
| SCHEMBL12500579 | 0.70 | — | — | |
| SCHEMBL786337 | 0.69 | HCAR2 (0.50) | HCAR2HCAR3PRKAB2PRKAG1PRKAA2 | |
| SCHEMBL2293236 | 0.68 | — | — | |
| SCHEMBL23943006 | 0.67 | ESR1 (0.39) | — | |
| SCHEMBL19400917 | 0.67 | — | — | |
| SCHEMBL20681842 | 0.67 | — | — | |
| SCHEMBL1269500 | 0.67 | — | — | |
| Hydrochloric Acid SCHEMBL31389982 | 0.67 | HCAR2 (0.48) | HCAR2HCAR3PRKAB2PRKAG1PRKAA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4146645-B1 | 3-AZABICYCLO(3.1.0)HEXANE DERIVATIVES HAVING KDM5 INHIBITORY ACTIVITY AND USE THEREOF | ONO PHARMACEUTICAL CO (JP) | 2025-06-25 | — | — | EP | disclosed |
| EP-4471027-A1 | 3-AZABICYCLO(3.1.0)HEXANE DERIVATIVES HAVING KDM5 INHIBITORY ACTIVITY AND USE THEREOF | ONO Pharmaceutical Co., Ltd. (JP) | 2024-12-04 | — | — | EP | disclosed |
| CN-115461338-B | 3-azabicyclo (3.1.0) hexane derivatives having KDM5 inhibitory activity and uses thereof | 小野药品工业株式会社 | 2024-02-20 | — | — | CN | disclosed |
| US-11691968-B2 | Compound having KDM5 inhibitory activity and pharmaceutical use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2023-07-04 | — | — | US | disclosed |
| EP-4146645-A1 | 3-AZABICYCLO(3.1.0)HEXANE DERIVATIVES HAVING KDM5 INHIBITORY ACTIVITY AND USE THEREOF | ONO Pharmaceutical Co., Ltd. (JP) | 2023-03-15 | — | — | EP | disclosed |
| CN-115461338-A | 3-azabicyclo (3.1.0) hexane derivatives having KDM5 inhibitory activity and uses thereof | 小野药品工业株式会社 | 2022-12-09 | — | — | CN | disclosed |
| US-20220289751-A1 | COMPOUND HAVING KDM5 INHIBITORY ACTIVITY AND PHARMACEUTICAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2022-09-15 | — | — | US | disclosed |
| EP-3999183-A1 | COMPOUND HAVING KDM5 INHIBITORY ACTIVITY AND PHARMACEUTICAL USE THEREOF | Ono Pharmaceutical Co., Ltd. (JP) | 2022-05-25 | — | — | EP | disclosed |
| US-20210137886-A1 | INHIBITORS OF METALLO-BETA-LACTAMASES | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2021-05-13 | — | — | US | disclosed |
| EP-3630777-A1 | INHIBITORS OF METALLO-BETA-LACTAMASES | Oxford University Innovation Limited (GB) | 2020-04-08 | — | — | EP | disclosed |
| WO-2018215800-A1 | INHIBITORS OF METALLO-BETA-LACTAMASES | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2018-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210137886-A1 | INHIBITORS OF METALLO-BETA-LACTAMASES | MGAM, GAA, LCT | HCAR2 4543/4885HCAR3 4660/4885PRKAB2 2817/4885 |
| US-11691968-B2 | Compound having KDM5 inhibitory activity and pharmaceutical use thereof | KDM5A, KDM5B, KDM5D | HCAR2 1733/4885HCAR3 2210/4885PRKAB2 1758/4885 |
| US-20220289751-A1 | COMPOUND HAVING KDM5 INHIBITORY ACTIVITY AND PHARMACEUTICAL USE THEREOF | KDM5A, KDM1B, KDM5D | HCAR2 2298/4885HCAR3 2618/4885PRKAB2 1775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.